公开(公告)号：US20240358725A1

公开(公告)日：2024-10-31

申请号：US18682693

申请日：2022-08-10

申请人： AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.

发明人： Babak BABAN ,  Jack YU

IPC分类号： A61K31/00 ,  A61K9/00 ,  A61P35/00

CPC分类号： A61K31/658 ,  A61K9/008 ,  A61P35/00

摘要： A method of reducing tumor size in a subject in need thereof, comprising administering to the subject an effective amount of cannabidiol effective to inhibit tumor growth.

公开(公告)号：US12048745B2

公开(公告)日：2024-07-30

申请号：US16400595

申请日：2019-05-01

申请人： Augusta University Research Institute, Inc.

发明人： Samir N. Khleif ,  Vivek Verma ,  Seema Gupta

IPC分类号： A61K39/395 ,  A61K9/00 ,  A61K38/19 ,  A61P35/00 ,  G01N33/49 ,  A61K39/00 ,  A61K45/06 ,  G01N15/01 ,  G01N15/10

CPC分类号： A61K39/39558 ,  A61K9/0019 ,  A61K38/195 ,  A61P35/00 ,  G01N33/4915 ,  A61K2039/80 ,  A61K45/06 ,  G01N15/01 ,  G01N2015/1006 ,  G01N2800/52

摘要： Compositions and methods of their use to detect and treat anti-PD1 therapy resistance are provided herein. Compositions that immunospecifically bind and deplete dysfunctional T cells are provided. The dysfunctional T cells that are depleted include CD38+PD-1+ T cells, CD38+CD8+ T-cells, or both. The dysfunctional T cells can be depleted, for example, by administering an antibody or fusion protein that specifically binds to dysfunctional T cells and promotes their depletion. In one embodiment the antibody is a bispecific antibody that can be specific for CD38 and CD8, or it can be specific for CD38 and PD-1. Also disclosed is a method of detecting and treating anti-PD1 therapy resistance by measuring the amount of CD38+PD1+CD8 T cells in blood or tissue samples obtained from a subject prior to anti-PD1 therapy and administering an anti-CD38/CD8 or anti-CD38/PD-1 depleting/blocking antibody to the subject prior to anti-PD1 therapy.

公开(公告)号：US20240226124A9

公开(公告)日：2024-07-11

申请号：US18546720

申请日：2022-02-16

申请人： AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.

发明人： Babak BABAN ,  Jack YU ,  Krishnan M. DHANDAPANI

IPC分类号： A61K31/00 ,  A61P25/28

CPC分类号： A61K31/658 ,  A61P25/28

摘要： A method of reducing symptoms of a neurodegenerative disease comprising administering an effective amount of cannabidiol to a subject in need thereof to improved cognitive function and ameliorated the pathophysiology of the neurodegenerative disease.

公开(公告)号：US20240150311A1

公开(公告)日：2024-05-09

申请号：US18542302

申请日：2023-12-15

申请人： Augusta University Research Institute, Inc.

发明人： Mark Hamrick ,  Carlos Isales ,  Iryna Lebedyeva

IPC分类号： C07D317/60 ,  C07C69/66 ,  C07D311/06 ,  C07D405/12

CPC分类号： C07D317/60 ,  C07C69/66 ,  C07D311/06 ,  C07D405/12

摘要： Provided herein are compounds that inhibit IDO1 and methods of use thereof. Also provided are pharmaceutical compositions and medicaments that include the compounds described herein as well as methods of treating sarcopenia or age-related muscle loss.

公开(公告)号：US11957673B2

公开(公告)日：2024-04-16

申请号：US16645293

申请日：2018-09-06

申请人： Augusta University Research Institute, Inc.

发明人： Samir Khleif ,  Mikayel Mkrtichyan

IPC分类号： C07D401/12 ,  A61K31/42 ,  A61K31/436 ,  A61K31/4709 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/573 ,  A61K35/17 ,  A61K38/13 ,  A61K38/17 ,  A61K39/395 ,  A61P37/06

CPC分类号： A61K31/4709 ,  A61K31/42 ,  A61K31/436 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/573 ,  A61K35/17 ,  A61K38/13 ,  A61K38/1774 ,  A61K38/1793 ,  A61K39/3955 ,  A61P37/06 ,  C07D401/12

摘要： Compositions and methods of selectively activating Akt3 are provided.

公开(公告)号：US20240100076A1

公开(公告)日：2024-03-28

申请号：US18262174

申请日：2022-01-19

申请人： Augusta University Research Institute, Inc.

发明人： Robert Yu ,  Yutaka Itokazu

IPC分类号： A61K31/7032 ,  A61P25/16 ,  A61P25/28

CPC分类号： A61K31/7032 ,  A61P25/16 ,  A61P25/28

摘要： Methods and compositions for treating neurodegenerative diseases are provided. In one embodiment, the method includes administering gangliosides into the brain of a mammal in need of such treatment. The gangliosiges are preferably GM1 and GD3 gangliosides. The gangliosides are intranasally administered in an amount effective to delay and/or prevent disease progression, and to increase the resilience of brains by promoting adult neurogenesis by gangliosides.

公开(公告)号：US11780921B2

公开(公告)日：2023-10-10

申请号：US17210117

申请日：2021-03-23

申请人： Augusta University Research Institute, Inc.

发明人： Samir Khleif ,  Mikayel Mkrtichyan

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K39/00

CPC分类号： C07K16/2818 ,  A61P35/00 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/92

摘要： Antibodies and antigen binding fragments thereof are provided that immunospecifically bind to PD-1, preferably human or mouse PD-1, and induce or promote an immune response that activates immune cell proliferation or activity. Contrary to the existing paradigm that PD-1 exclusively promotes a suppressive immune response, the disclosed antibodies and antigen binding fragments thereof, immunospecifically bind to PD-1 and cause an activating signal to be delivered to the immune cell that activates the immune cell rather than suppressing the immune cell. In one embodiment, the disclosed antibodies and antigen binding fragments thereof specifically bind to PD-1 expressed on immune cells. The binding of the disclosed antibodies and antigen binding fragments thereof to PD-1 on immune cells causes an activating signal to be transmitted into the immune cell, for example a signal that enhances or promotes cytokine production and/or activation of immune cell proliferation. Immune cells that express PD-1, include but are not limited to B and T cells as well as myeloid-derived cells. In one embodiment, the immune cell is a T cell, preferably a CD8+ T cell.

公开(公告)号：US20230277583A1

公开(公告)日：2023-09-07

申请号：US18179069

申请日：2023-03-06

申请人： Augusta University Research Institute, Inc. ,  Hillhurst Biopharmaceuticals, Inc.

发明人： Pamela Martin ,  Ravirajsinh Jadeja ,  Andrew Gomperts

IPC分类号： A61K33/00 ,  A61P27/02 ,  A61P3/10

CPC分类号： A61K33/00 ,  A61P27/02 ,  A61P3/10

摘要： Enteral formulations containing including therapeutically effective amount carbon monoxide, and methods of use thereof, for treatment of ocular diseases and disorders are provided. The formulations can be administered in a subject in need thereof in an effective amount to reduce or prevent an ocular disease in the subject, and thus reduce one or more symptoms of disease, disorder, or illness associated with the disease. In some embodiments, the formulation is administered orally.

公开(公告)号：US20230159471A1

公开(公告)日：2023-05-25

申请号：US18156316

申请日：2023-01-18

申请人： Augusta University Research Institute, Inc.

发明人： Siva PANDA

IPC分类号： C07D241/24 ,  C07D401/12 ,  C07D413/12 ,  A61P31/06 ,  C07D401/14

CPC分类号： C07D241/24 ,  C07D401/12 ,  C07D413/12 ,  A61P31/06 ,  C07D401/14 ,  A61K9/0053

摘要： Pyrazinamide (PZA) conjugates and hybrids are provided herein. The PZA conjugates are useful for treating bacterial infections. In one embodiment, the PZA conjugates are useful for treating tuberculosis.

公开(公告)号：US11324774B2

公开(公告)日：2022-05-10

申请号：US16237885

申请日：2019-01-02

申请人： Augusta University Research Institute, Inc.

发明人： Paul O'Connor ,  Ryan Harris

IPC分类号： A61K33/00 ,  A61K31/198 ,  A61K9/08 ,  A61K9/00 ,  A61P3/10 ,  A61P9/12 ,  A61P9/10 ,  A61P3/04 ,  A61P29/00

摘要： Compositions of alkaline salts and metabolic acid inducers and methods of use thereof are provided. The disclosed compositions may be used for stimulating vagal nerve efferent pathways, treating or preventing an inflammatory response or an autoimmune disorder, inhibiting or reducing one or more inflammatory M1 macrophages and/or one or more inflammatory neutrophils in the blood, promoting polarization of macrophages from a pro-inflammatory M1 state to an anti-inflammatory M2 state, and treating or preventing cardiovascular disease or metabolic disorders.